Show simple item record

dc.contributor.authorResino, Salvador 
dc.contributor.authorBellón, José M
dc.contributor.authorAsensio del Barrio, Cristina 
dc.contributor.authorMicheloud, Dariela
dc.contributor.authorMiralles, Pilar
dc.contributor.authorVargas, Ana
dc.contributor.authorCatalán, Pilar
dc.contributor.authorLópez, Juan C
dc.contributor.authorAlvarez, Emilio
dc.contributor.authorCosin, Jaime
dc.contributor.authorLorente, Raquel
dc.contributor.authorMuñoz-Fernández, María A
dc.contributor.authorBerenguer, Juan
dc.date.accessioned2019-02-08T10:11:18Z
dc.date.available2019-02-08T10:11:18Z
dc.date.issued2010-08-19
dc.identifier.citationBMC Infect Dis. 2010 Aug 19;10:244.es_ES
dc.identifier.issn1471-2334es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7149
dc.description.abstractBACKGROUND: Hyaluronic acid (HA) serum levels correlate with the histological stages of liver fibrosis in hepatitis C virus (HCV) monoinfected patients, and HA alone has shown very good diagnostic accuracy as a non-invasive assessment of fibrosis and cirrhosis. The aim of this study was to evaluate serum HA levels as a simple non-invasive diagnostic test to predict hepatic fibrosis in HIV/HCV-coinfected patients and to compare its diagnostic performance with other previously published simple non-invasive indexes consisting of routine parameters (HGM-1, HGM-2, Forns, APRI, and FIB-4). METHODS: We carried out a cross-sectional study on 201 patients who all underwent liver biopsies and had not previously received interferon therapy. Liver fibrosis was determined via METAVIR score. The diagnostic accuracy of HA was assessed by area under the receiver operating characteristic curves (AUROCs). RESULTS: The distribution of liver fibrosis in our cohort was 58.2% with significant fibrosis (F≥2), 31.8% with advanced fibrosis (F≥3), and 11.4% with cirrhosis (F4). Values for the AUROC of HA levels corresponding to significant fibrosis (F≥2), advanced fibrosis (F≥3) and cirrhosis (F4) were 0.676, 0.772, and 0.863, respectively. The AUROC values for HA were similar to those for HGM-1, HGM-2, FIB-4, APRI, and Forns indexes. The best diagnostic accuracy of HA was found for the diagnosis of cirrhosis (F4): the value of HA at the low cut-off (1182 ng/mL) excluded cirrhosis (F4) with a negative predictive value of 99% and at the high cut-off (2400 ng/mL) confirmed cirrhosis (F4) with a positive predictive value of 55%. By utilizing these low and high cut-off points for cirrhosis, biopsies could have theoretically been avoided in 52.2% (111/201) of the patients. CONCLUSIONS: The diagnostic accuracy of serum HA levels increases gradually with the hepatic fibrosis stage. However, HA is better than other simple non-invasive indexes using parameters easily available in routine clinical practice only for the diagnosing of cirrhosis.es_ES
dc.description.sponsorshipSources of financial support: This work was supported by grants from Instituto de Salud Carlos III (Ref. PI052411; Ref. PI07/90201, Ref. UIPY 1467/07) and Fundación para la Investigación y la Prevención del SIDA en España (FIPSE) (Ref. 36650/07) to SR. And from Fondo de Investigación Sanitaria (FIS) (Ref. ISCIII-RETIC RD06/006; Ref. PI080928) and FIPSE (Ref. 36443/03; Ref. 36702/07) to JB. Fundación para la Investigación y la Prevención del SIDA en España (FIPSE 24534/05, 24632/07), Fondo de Investigación Sanitaria (FIS) of Ministerio de Ciencia e Innovación FIS (PI052476, PI061479); Red RIS RD06-0006-0035; Fundación Caja Navarra, Comunidad de Madrid (S-SAL-0159-2006) and Task Force in Europe for Drug Development for the Young (TEDDY) to MAMF.es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult es_ES
dc.subject.meshBiomarkers es_ES
dc.subject.meshBiopsy es_ES
dc.subject.meshCross-Sectional Studies es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHepatitis C, Chronic es_ES
dc.subject.meshHumans es_ES
dc.subject.meshHyaluronic Acid es_ES
dc.subject.meshLiver es_ES
dc.subject.meshLiver Cirrhosis es_ES
dc.subject.meshMale es_ES
dc.subject.meshPredictive Value of Tests es_ES
dc.subject.meshSerum es_ES
dc.subject.meshSeverity of Illness Index es_ES
dc.titleCan serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID20723207es_ES
dc.format.volume10es_ES
dc.format.number1es_ES
dc.format.page244es_ES
dc.identifier.doi10.1186/1471-2334-10-244es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en España
dc.contributor.funderFondo de Investigaciones Sanitarias
dc.contributor.funderFundacion Caja Navarra
dc.contributor.funderGobierno de la Comunidad Autónoma de Madrid
dc.description.peerreviewedes_ES
dc.identifier.e-issn1471-2334es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/1471-2334-10-244es_ES
dc.identifier.journalBMC infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Agencia de Evaluación de Tecnologías Sanitariases_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI052411es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI07/90201es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/UIPY 1467/07es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RETIC RD06/006es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI080928es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI052476es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI061479es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD06-0006-0035es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional